Research ArticleCardiovascular Genomics

A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease

See allHide authors and affiliations

Science Translational Medicine  01 Jun 2016:
Vol. 8, Issue 341, pp. 341ra76
DOI: 10.1126/scitranslmed.aad3744

Log in to view full text

Log in through your institution

Log in through your institution

Stay Connected to Science Translational Medicine

Navigate This Article